Erratum to: Multiple sclerosis (Nature Reviews Disease Primers, (2018), 4, 1, (43), 10.1038/s41572-018-0041-4)
Academic Article
Publication Date:
2018
abstract:
In the originally published version of this article, in Table 4, Ocrelizumab was incorrectly referred to as an anti-CD25 antibody. This has been corrected in the HTML and PDF versions of the article to an anti-CD20 antibody.
Iris type:
1.1.3. Articolo in Rivista - Editorial, Comment, Reply
List of contributors:
Filippi, M.; Bar-Or, A.; Piehl, F.; Preziosa, P.; Solari, A.; Vukusic, S.; Rocca, M. A.
Published in: